SLP7111228

SLP7111228 is a selective sphingosine kinase 1 (SphK1) inhibitor and anti-inflammatory agent. SLP7111228 selectively inhibits SphK1 and reduces the production of sphingosine-1-phosphate. SLP7111228 decreases lipopolysaccharide-induced TNFα and IL-1β levels. SLP7111228 alleviates obliterative pulmonary arteriopathy, increases cardiac index and decreases total pulmonary vascular resistance index. SLP7111228 can be used in research related to neuroinflammatory diseases and pulmonary hypertension^[1][2]. In Vitro:SLP7111228 (1 µM; 30 min pre-incubation, 4 h LPS incubation) significantly reduces LPS-induced IL-1β mRNA expression in BV2 mouse microglia cells, with a non-significant reduction in TNFα mRNA expression^[1]. In Vivo:SLP7111228 (10 mg/kg; i.p.; daily; 3 weeks) reduces plasma S1P levels, reverses occlusive pulmonary arteriopathy, and improves cardiac function in late-stage Su/Hx/Nx PAH rats, without reducing right ventricular systolic pressure or hypertrophy^[2].